Patients with PsA who are treated with CTT are not at a greater risk for serious or opportunistic infections compared with standard therapy.
Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback